argenx (ARGX) Research Hub

argenx (ARGX) trades on NASDAQ, NL in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 984.39 USD (-1.79%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 50.16, market cap 53.37B. This hub links to the full technical, earnings and options research available for ARGX.

Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, NL
Last close984.39 USD (-1.79%)
52-week range832.71 USD – 1,070.81 USD
Trend regimeRange
14-day RSI66.5 (Bullish)
Trailing P/E50.16
Market cap53.37B
Dividend yield0.00%
Next earnings2026-07-23

Available research for ARGX

Earnings

ARGX earnings: next report 2026-07-23, real EPS beat/miss history, analyst consensus Buy, P/E 50.16. Updated 2026-07-23.

Options: Covered Call

Covered Call on ARGX: how it works, illustrative setup around the real 984.39 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on ARGX: how it works, illustrative setup around the real 984.39 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on ARGX: how it works, illustrative setup around the real 984.39 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

ARGX technical analysis: range, last 984.39 USD, RSI 66.5, 52w range 832.71 USD–1,070.81 USD, real support/resistance. Updated 2026-09-11.

Frequently asked questions

What sector is ARGX in?

argenx (ARGX) is classified under Healthcare (Biotechnology), listed on NASDAQ, NL.

Is ARGX in an uptrend or downtrend?

As of 2026-09-11, ARGX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is ARGX's trailing P/E ratio?

ARGX's trailing P/E is 50.16, with a market cap of 53.37B. See the earnings research page for full valuation detail.

When does ARGX next report earnings?

ARGX is next scheduled to report earnings on 2026-07-23.